Document Detail

Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
MedLine Citation:
PMID:  22531540     Owner:  NLM     Status:  MEDLINE    
We herein describe a case of drug-induced interstitial lung disease (ILD) following treatment with erlotinib. The plasma trough concentration of erlotinib at the time of the ILD diagnosis was extremely elevated compared with the plasma maximum concentration on day 1. We hypothesized that this phenomenon was associated with the pharmacodynamic interaction with a concomitant drug. The present case indicates that erlotinib-induced ILD was associated with a high plasma concentration of erlotinib. Oncologists should be aware of the possibility of ILD induced by erlotinib, especially for patients with co-morbidities.
Yukari Tsubata; Akinobu Hamada; Akihisa Sutani; Takeshi Isobe
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of cancer research and therapeutics     Volume:  8     ISSN:  1998-4138     ISO Abbreviation:  J Cancer Res Ther     Publication Date:    2012 Jan-Mar
Date Detail:
Created Date:  2012-04-25     Completed Date:  2012-08-22     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101249598     Medline TA:  J Cancer Res Ther     Country:  India    
Other Details:
Languages:  eng     Pagination:  154-6     Citation Subset:  IM    
Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Agents / adverse effects*,  blood,  therapeutic use
Carcinoma, Non-Small-Cell Lung / complications*,  drug therapy
Lung Diseases, Interstitial / chemically induced*,  diagnosis*
Lung Neoplasms / complications*,  drug therapy
Protein Kinase Inhibitors / adverse effects*,  blood,  therapeutic use
Quinazolines / adverse effects*,  blood,  therapeutic use
Reg. No./Substance:
0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; 0/Quinazolines; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Obesity as the initial manifestation of central nervous system relapse of acute lymphoblastic leukem...
Next Document:  Giant lipoblastoma of the thigh: A rare soft tissue tumor in an infant.